Promega to Showcase Oncology Research Tools and Companion Diagnostics at AACR Annual Meeting 2026

Key Takeaways

• Lumit® hKi‑67 assay offers rapid, plate‑based cell‑proliferation readouts
• TarSeer™ BRETSA™ provides tracer‑free, live‑cell target engagement measurement
• OncoMate® MSI Dx gains FDA and NMPA clearance for companion diagnostics
• Automated Maxwell® HT protocols streamline nucleic‑acid extraction on KingFisher platforms

Pulse Analysis

The American Association for Cancer Research’s 2026 meeting draws thousands of investigators seeking the latest in tumor biology, immunotherapy and diagnostics. By securing a prominent booth and a slate of poster presentations, Promega signals its intent to be a central player in the oncology ecosystem. The company’s portfolio now spans from early‑stage cell‑health assays to clinically validated companion diagnostics, offering researchers a seamless transition from discovery to translational studies.

Promega’s highlighted technologies address critical bottlenecks in drug development. The Lumit® hKi‑67 immunoassay delivers high‑throughput, quantitative proliferation data without the variability of traditional immunohistochemistry. Meanwhile, the TarSeer™ BRETSA™ system replaces costly fluorescent tracers with a bioluminescence‑resonance energy transfer readout, enabling ultra‑sensitive detection of compound‑protein interactions in live cells. The newly approved OncoMate® MSI Dx Analysis System brings a standardized, FDA‑cleared assay for microsatellite instability, a key biomarker for immunotherapy response, to both U.S. and Chinese markets.

Automation and multiplexing are the next frontier, and Promega’s integration of Maxwell® HT chemistry into KingFisher™ Flex and Apex instruments exemplifies this trend. Pre‑configured protocols reduce hands‑on time and variability, supporting large‑scale screening campaigns. Combined with the red‑shifted NanoPrism™ luciferase for dual‑color bioluminescence, researchers can now conduct more complex, multiplexed assays in a single workflow. These advancements not only accelerate discovery timelines but also enhance data robustness, positioning Promega to capture a larger share of the growing oncology‑research market.